$Silexion Therapeutics (SLXN.US)$ me adding tomorrow above 1.50

$Silexion Therapeutics (SLXN.US)$ will climb tomorrow me buying

$Silexion Therapeutics (SLXN.US)$ Silexion Announces Completion Of SIL204 Development Plan For KRAS Cancers; Presentation Scheduled At NeauxCancer 2025 Conference In New Orleans
Benzinga· 1 min ago
Silexion Therapeutics Corp. ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the company'...

$Silexion Therapeutics (SLXN.US)$
Revolutionary KRAS Cancer Treatment: Silexion Expands Development Strategy for SIL204

$Silexion Therapeutics (SLXN.US)$
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
Friday, 21st March at 8:30 am
Grand Cayman, Cayman Islands, March 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced it has completed an expanded dev...

$Silexion Therapeutics (SLXN.US)$
Silexion's Pancreatic Cancer Breakthrough: 56% Response Rate Despite Financial Headwinds

$Silexion Therapeutics (SLXN.US)$
PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment
Monday, 17th March at 8:15 am
Silexion Therapeutics (NASDAQ: SLXN) has reported breakthrough preclinical data for its SIL204 therapeutic candidate, showing promising results in treating KRAS-driven cancers, particularly pancreatic cancer. The orthotopic model studies demonstrated:
~70% reduc...

$Silexion Therapeutics (SLXN.US)$
considering the overall market this is
moving higher

$Silexion Therapeutics (SLXN.US)$ yes big curl up coming